Trial Profile
A Phase 2 study of safety of Rivaroxaban compared with Low Molecular Weight Heparin (LMWH) for acute therapy of cancer-associated venous thromboembolism
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 18 Apr 2022
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Dalteparin sodium
- Indications Venous thromboembolism
- Focus Adverse reactions
- Acronyms ACAT
- 05 Feb 2018 Status changed from not yet recruiting to recruiting.
- 03 Mar 2017 New trial record